Ann: Completion of Autoimmune Program with Ginkgo Bioworks, page-12

Positive move for them to make the webinar more easily accessible by holding it on Zoom. Makes no sense to me for them to be hiding these presentations as they seem to have done for the last few showings. Hopefully they will stick a copy of the webinar up on the front page of their website.

I have to say I was disappointed with how the MD, Luke Reid, went in the recent s-trawman interview (here's a hint: that word is prohibited on hc). Really worried when he said that he accepts that Microba will lose its competitive advantage but it wont matter as long as it is the first mover. Yeah right, tell that to Blueberry investors. Also concerned by his leaps of faith: currently they sell a couple of thousand tests in a year but LR is confident they can knock out a million or so tests, presumably a year, out of the US (sure, sounds good, but give us a hint on how you will achieve that); and, their first development product is not yet in phase two testing but LR compared it to something that sold for $11b (pretty much every medtech could use the same blue sky comparison, so how are the odds any different for Microba?).

Clearly the market is not buying the Microba pitch, as it now is. In that recent interview I thought LR too often lapsed into GP nerd talk. It may be that he is right in identifying GPs as the primary customers for Microba tests but I am pretty sure the interview was intended to reach out to potential investors. And the brutal reality is that while most fund managers and retail investors did not do as well at high school as the average GP Microba needs to attract that "dumb" money (so don't talk over us). I genuinely think Microba needs to bring in some marketing expertise as the current messaging is missing the mark.